Effects of dopaminergic compounds on carbonic anhydrase isozymes I, II, and VI

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 3, 2012, Pages 365-369

  Şentürk, Murat ^a   Ekinci, Deniz ^b   Göksu, Süleyman ^c   Supuran, Claudiu T ^d  

^a AGRI IBRAHIM CECEN UNIVERSITY   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^c ATATÜRK UNIVERSITY   (Turkey)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbonic anhydrase; Dopaminergic; HCA I; HCA II; Inhibitor

Indexed keywords

2 AMINO 5 BROMOINDAN; 2 AMINO 5,6 DIBROMOINDAN; 2 AMINO 5,6 DIHYDROXYTETRALIN; 2 AMINO 5,6 DIMETHOXYINDAN; 2 AMINO 6,7 DIHYDROXYTETRALIN; ACETAZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE VI; CARBONATE DEHYDRATASE VI INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; SEROTONIN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULE; PRIORITY JOURNAL; PROTEIN PURIFICATION;

CARBONIC ANHYDRASE I; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOENZYMES; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860360752     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.591290     Document Type: Article

References (36)

1. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-181. (Pubitemid 351194064)
2. Supuran CT. Carbonic anhydrases-an overview. Curr Pharm Des 2008;14:603-614.
3. Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des 2008;14:641-648. (Pubitemid 351736443)
4. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995;64:375-401.
5. Ozensoy O, Arslan O, Sinan SO. A new method for purification of carbonic anhydrase isozymes by affinity chromatography. Biochemistry Mosc 2004;69:216-219.
6. Bayram E, Senturk M, Kufrevioglu OI, Supuran CT. In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem 2008;16:9101-9105.
7. Senturk M, Talaz O, Ekinci D, Cavdar H, Kufrevioglu OI. In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg Med Chem Lett 2009;19:3661-3663.
8. Parkkila S, Parkkila AK. Carbonic anhydrase in the alimentary tract. Roles of the different isozymes and salivary factors in the maintenance of optimal conditions in the gastrointestinal canal. Scand J Gastroenterol 1996;31:305-317. (Pubitemid 26117752)
9. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199-229. (Pubitemid 39004275)
10. Nair SK, Ludwig PA, Christianson DW. Two-site binding of phenol in the active site of human carbonic anhydrase II: structural implications for substrate association. J Am Chem Soc 1994;116:3659-3660.
11. Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV). Bioorg Med Chem Lett 2008;18:1583-1587. (Pubitemid 351320621)
12. Innocenti A, Vullo D, Scozzafava A, Supuran CT. Inhibition of human mitochondrial carbonic anhydrases VA and VB with para- (4-phenyltriazole-1-yl)- benzenesulfonamide derivatives Bioorg Med Chem 2008;16:7424-7428.
13. Innocenti A, Hilvo M, Scozzafava A, Parkkila S, Supuran CT. Carbonic anhydrase inhibitors: Inhibition of the new membraneassociated isoform XV with phenols. Bioorg Med Chem Lett 2008;18:3593-3596. (Pubitemid 351790729)
14. Coban TA, Beydemir S, Gulcin I, Ekinci D. The inhibitory effect of ethanol on Carbonic Anhydrase isoenzymes: An in vivo and in vitro study J Enzyme Inhib Med Chem 2008; 23:266-270. (Pubitemid 351404847)
15. Ekinci D, Ceyhun SB, Senturk M, Erdem D, Kufrevioglu OI, Supuran CT. Characterization and anions inhibition studies of an a-carbonic anhydrase from the teleost fish Dicentrarchus labrax. Bioorg Med Chem 2011;19:744-748.
16. Hilvo M, Tolvanen M, Clark A, Shen B, Shah GN, Waheed A et al. Characterization of CA XV, a new GPI-anchored form of carbonic anhydrase. Biochem J 2005;392:83-92. (Pubitemid 41689404)
17. Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, Innocenti A et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008;283:27799-27809.
18. Ekinci D, Beydemir S, Kufrevioglu OI. In vitro inhibitory effects of some heavy metals on human erythrocyte carbonic anhydrases. J Enzyme Inhib Med Chem 2007;22:745-750. (Pubitemid 350215081)
19. Haadsma-Svensson SR, Svensson KA. PNU-99194A: a preferential dopamine D3 receptor antagonist. CNS Drug Rev 1998;4:42-57.
20. Cannon JG. Dopamine agonists: structure-activity relationships. Prog Drug Res 1985;29:303-414. (Pubitemid 16165831)
21. Gray AP, Reit E, Ackerly JA. Conformational requirements for direct adrenergic stimulation. J Med Chem 1973;16:1023-1027.
22. Jagoe CT, Kreifels SE, Li J. Covalent binding of catechols to src family SH2 domains. Bioorg Med Chem Lett 1997;7:113-116. (Pubitemid 27046405)
23. Richter H, Schenck M, German Patent 952441 1956; Chem. Abstr., 1959, 53, 2190e.
24. Haadsma-Svensson SR, Cleek KA, Dinh DM, Duncan JN, Haber CL, Huff RM et al. Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy- N-alkyl- and N-alkylaryl-substituted 2-aminoindans. J Med Chem 2001;44:4716-4732. (Pubitemid 33144481)
25. Kivela J, Parkkila S, Waheed A, Parkkila AK, Sly WS, Rajaniemi H. Secretory carbonic anhydrase isoenzyme (CA VI) in human serum. Clin Chem 1997;43:2318-2322. (Pubitemid 28022967)
26. Verpoorte JA, Mehta S, Edsall JT. Esterase activities of human carbonic anhydrases B and C. j Biol Chem 1967;242:4221-4229.
27. Lineweaver H, Burk D. The determination of enzyme dissocation constants. J Am Chem Soc 1934;56:658-666.
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976;72:248-254.
29. Laemmli DK. Cleavage of structural proteins during in assembly of the head of Bacteriophage T4. Nature 1970;227:680-685.
30. Vomasta D, Innocenti A, König B, Supuran CT. Carbonic anhydrase inhibitors: two-prong versus mono-prong inhibitors of isoforms I, II, IX, and XII exemplified by photochromic cis- 1,2-alpha-dithienylethene derivatives. Bioorg Med Chem Lett 2009;19:1283-1286.
31. Vullo D, Innocenti A, Nishimori I, Scozzafava A, Kaila K, Supuran CT. Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. Bioorg Med Chem Lett 2007;17:4107-4112. (Pubitemid 47023151)
32. Ilies M, Scozzafava A, Supuran CT. Carbonic anhydrase activators. In Carbonic anhydrase- Its inhibitors and activators; Supuran CT, Scozzafava A, Conway J, Eds.; CRC Press: Boca Raton (FL), USA, 2004; p 317.
33. Innocenti A, Maresca A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: thioxolone versus sulfonamides for obtaining isozymeselective inhibitors? Bioorg Med Chem Lett 2008;18:3938-3941.
34. Hisar O, Beydemir S, Gülç in I, Küfrevioglu OI, Supuran CT. Effects of low molecular weight plasma inhibitors of rainbow trout (Oncorhynchus mykiss) on human erythrocyte carbonic anhydrase-II isozyme activity in vitro and rat erythrocytes in vivo. J Enzyme Inhib Med Chem 2005;20:35-39. (Pubitemid 40520614)
35. Abdülkadir Coban T, Beydemir S, Gülcin I, Gücin I, Ekinci D, Innocenti A et al. Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV. Bioorg Med Chem 2009;17:5791-5795.
36. Ekinci D, Beydemir S, Alim Z. Some drugs inhibit in vitro hydratase and esterase activities of human carbonic anhydrase-I and II. Pharmacol Rep 2007;59:580-587.